Editing Dimethyltryptamine (section)

===Tolerance===
Unlike other classical psychedelics, [[drug tolerance|tolerance]] does not seem to develop to the subjective effects of DMT.<ref name="CarbonaroGatch2016" /><ref name="Halberstadt2015">{{cite journal | vauthors = Halberstadt AL | title = Recent advances in the neuropsychopharmacology of serotonergic hallucinogens | journal = Behav Brain Res | volume = 277 | issue = | pages = 99–120 | date = January 2015 | pmid = 25036425 | doi = 10.1016/j.bbr.2014.07.016 | pmc = 4642895 | url = }}</ref> Studies report that DMT did not exhibit tolerance upon repeated administration of twice a day sessions, separated by 5{{nbsp}}hours, for 5{{nbsp}}consecutive days; [[Field_research|field reports]] suggests a [[Refractory_period_(physiology)|refractory period]] of only 15 to 30{{nbsp}}minutes, while the [[Pharmacokinetics#Metrics|plasma levels]] of DMT was nearly undetectable 30{{nbsp}}minutes after [[intravenous administration]].<ref name="Halberstadt2015" /><ref name="StrassmanQuallsBerg1996">{{cite journal | vauthors = Strassman RJ, Qualls CR, Berg LM | title = Differential tolerance to biological and subjective effects of four closely spaced doses of N,N-dimethyltryptamine in humans | journal = Biol Psychiatry | volume = 39 | issue = 9 | pages = 784–795 | date = May 1996 | pmid = 8731519 | doi = 10.1016/0006-3223(95)00200-6 | url = }}</ref> Another study of four closely spaced DMT infusion sessions with 30{{nbsp}}minute intervals also suggests no tolerance buildup to the psychological effects of the compound, while [[heart rate]] responses and [[Neuroendocrinology|neuroendocrine]] effects were diminished with repeated administration.<ref name="Halberstadt2015" /><ref name="StrassmanQuallsBerg1996" /> Similarly to DMT by itself, tolerance does not appear to develop to [[ayahuasca]].<ref name="DosSantosHallak2024">{{cite journal | vauthors = Dos Santos RG, Hallak JE | title = Ayahuasca: pharmacology, safety, and therapeutic effects | journal = CNS Spectr | volume = 30| issue = 1| pages = e2 | date = November 2024 | pmid = 39564645 | doi = 10.1017/S109285292400213X | url = }}</ref><ref name="DosSantosGrasaValle2012">{{cite journal | vauthors = Dos Santos RG, Grasa E, Valle M, Ballester MR, Bouso JC, Nomdedéu JF, Homs R, Barbanoj MJ, Riba J | title = Pharmacology of ayahuasca administered in two repeated doses | journal = Psychopharmacology (Berl) | volume = 219 | issue = 4 | pages = 1039–1053 | date = February 2012 | pmid = 21842159 | doi = 10.1007/s00213-011-2434-x | url = }}</ref> A fully hallucinogenic dose of DMT did not demonstrate [[cross-tolerance]] to human subjects who are highly tolerant to [[LSD]];<ref name="RosenbergIsbellMiner1963">{{cite journal |journal=Psychopharmacologia |vauthors=Rosenberg D, Isbell H, Miner E, and Logan C |doi=10.1007/BF00413244 |date=7 August 1963 |title=The effect of N,N-dimethyltryptamine in human subjects tolerant to lysergic acid diethylamide |volume=5 |issue=3 |url=https://link.springer.com/article/10.1007/BF00413244 |pages=223–224 |pmid=14138757 |s2cid=32950588 |access-date=4 May 2023 |archive-date=4 May 2023 |archive-url=https://web.archive.org/web/20230504011825/https://link.springer.com/article/10.1007/BF00413244 |url-status=live |url-access=subscription }}</ref> hence, research suggests that DMT exhibits unique pharmacological properties compared to other classical psychedelics.<ref name="StrassmanQuallsBerg1996" />